Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia

• Status: Withdrawn
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find a better, more convenient way to improve anemia results by increasing the amount of medication given at 3 week intervals. Researchers want to know if giving a higher dose of Procrit® and intravenous (IV) iron once every 3 weeks would give better results in treating anemia without the need for more office visits.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: James Graham Brown Cancer Center; University of Louisville
• Collaborators: James Graham Brown Cancer Center; University of Louisville
• Treatments: Epoetin Alfa; Ferric gluconate; Iron

Criteria

Inclusion Criteria:

• Histologically confirmed small cell or non small cell lung cancer

• Stage III or Stage IV lung cancer

• Platinum containing chemotherapy induced anemia (< 10 g/dl Hb)

• Cancer related anemia (<10 g/dl Hb) at time of initiation of chemotherapy

• ECOG performance status of 0,1, or 2

• Informed consent

• Age>18

• Expected to receive platinum based outpatient chemotherapy for at least nine weeks

Exclusion Criteria:

• Pregnant women

• Intolerance to epoetin alfa or parenteral iron

• More than 2 cycles of the planned platinum chemotherapy at time of enrollment

• Chronic GI bleed (> than 4 weeks positive hemoccult or gastroccult)

• Ferritin > 500 mg/dl

• Anemia due to other causes than cancer or chemotherapy

• Previous parenteral iron therapy

• Uncontrolled hypertension (systolic BP > 160, diastolic > 100 mmHg)